JPWO2022140150A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022140150A5 JPWO2022140150A5 JP2023537550A JP2023537550A JPWO2022140150A5 JP WO2022140150 A5 JPWO2022140150 A5 JP WO2022140150A5 JP 2023537550 A JP2023537550 A JP 2023537550A JP 2023537550 A JP2023537550 A JP 2023537550A JP WO2022140150 A5 JPWO2022140150 A5 JP WO2022140150A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- fusion polypeptide
- item
- target site
- deletion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128391P | 2020-12-21 | 2020-12-21 | |
| US63/128,391 | 2020-12-21 | ||
| PCT/US2021/063771 WO2022140150A1 (en) | 2020-12-21 | 2021-12-16 | Compositions and methods for site-directed mutagenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503249A JP2024503249A (ja) | 2024-01-25 |
| JP2024503249A5 JP2024503249A5 (https=) | 2024-12-23 |
| JPWO2022140150A5 true JPWO2022140150A5 (https=) | 2024-12-23 |
Family
ID=82158380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537550A Pending JP2024503249A (ja) | 2020-12-21 | 2021-12-16 | 部位特異的変異導入のための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240336904A1 (https=) |
| EP (1) | EP4262850A4 (https=) |
| JP (1) | JP2024503249A (https=) |
| KR (1) | KR20230122628A (https=) |
| CN (1) | CN116887853A (https=) |
| AU (1) | AU2021410632A1 (https=) |
| CA (1) | CA3202889A1 (https=) |
| WO (1) | WO2022140150A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012118717A2 (en) * | 2011-02-28 | 2012-09-07 | Seattle Children's Research Institute | Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption |
| RU2650811C2 (ru) * | 2012-02-24 | 2018-04-17 | Фред Хатчинсон Кэнсер Рисерч Сентер | Композиции и способы лечения гемоглобинопатии |
| US10000746B2 (en) * | 2013-05-31 | 2018-06-19 | Cellectis | LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof |
| US20180119174A1 (en) * | 2015-05-13 | 2018-05-03 | Seattle Children's Hospita (dba Seattle Children's Research Institute | Enhancing endonuclease based gene editing in primary cells |
| MX2018010924A (es) * | 2016-03-11 | 2019-02-13 | Bluebird Bio Inc | Células efectoras inmunitarias con edición genómica. |
| WO2018071565A1 (en) * | 2016-10-11 | 2018-04-19 | Bluebird Bio, Inc. | TCRa HOMING ENDONUCLEASE VARIANTS |
| IL313037A (en) * | 2017-05-25 | 2024-07-01 | 2Seventy Bio Inc | Cblb endonuclease variants, compositions, and methods of use |
| CN112533627A (zh) * | 2018-03-27 | 2021-03-19 | G+Flas 生命科学公司 | 序列特异性体内细胞靶向 |
| WO2020072059A1 (en) * | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| WO2020123371A2 (en) * | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Homing endonuclease variants |
| US20220280567A1 (en) * | 2019-06-14 | 2022-09-08 | 2Seventy Bio, Inc. | Compositions and methods for treating cancer |
-
2021
- 2021-12-16 US US18/258,021 patent/US20240336904A1/en active Pending
- 2021-12-16 KR KR1020237024378A patent/KR20230122628A/ko active Pending
- 2021-12-16 WO PCT/US2021/063771 patent/WO2022140150A1/en not_active Ceased
- 2021-12-16 AU AU2021410632A patent/AU2021410632A1/en not_active Abandoned
- 2021-12-16 CA CA3202889A patent/CA3202889A1/en active Pending
- 2021-12-16 CN CN202180093810.4A patent/CN116887853A/zh active Pending
- 2021-12-16 EP EP21911917.9A patent/EP4262850A4/en active Pending
- 2021-12-16 JP JP2023537550A patent/JP2024503249A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6352920B2 (ja) | 多重鎖キメラ抗原受容体およびその使用 | |
| JP7190096B2 (ja) | 遺伝子編集ｔ細胞及びその使用 | |
| Shinohara et al. | Structure and chromosomal localization of the human PD-1 gene (PDCD1) | |
| KR20210065141A (ko) | CRISPR/Cas 시스템을 기반으로 한 세포의 유전자 편집 방법 | |
| Bierer et al. | T cell adhesion, avidity regulation and signaling: a molecular analysis of CD2 | |
| KR102228828B1 (ko) | 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법 | |
| US10342829B2 (en) | Multi-chain chimeric antigen receptor and uses thereof | |
| KR102617818B1 (ko) | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 | |
| EP3025719B1 (en) | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases | |
| KR20210148293A (ko) | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 | |
| US20250250319A1 (en) | Chimeric transmembrane polypeptides comprising a tgf beta receptor extracellular domain, a transmembrane domain and an interleukin receptor 2 intracellular signalling domain and its use in therapy | |
| KR20230144570A (ko) | 면역 요법을 위한 동종이형 및 고활성 ｔ 세포의 조작 방법들 | |
| JP2023105045A (ja) | Ｂｒａｆ特異的ｔｃｒおよびその使用 | |
| Reynolds et al. | Lack of gene rearrangement and mRNA expression of the beta chain of the T cell receptor in spontaneous rat large granular lymphocyte leukemia lines. | |
| KR20210049119A (ko) | Kras 또는 her2 항원을 표적으로 하는 면역요법 | |
| KR20230066007A (ko) | 신규한 보조자극 도메인을 포함하는 키메라 항원 수용체 및 이의 용도 | |
| KR20210138043A (ko) | 고 결합 활성 wt1 t 세포 수용체 및 이의 용도 | |
| WO2019238016A1 (zh) | 一种嵌合单链分子及其应用 | |
| JP7558935B2 (ja) | メソテリンを標的とする免疫療法 | |
| CN114555790B (zh) | Wt-1特异性t细胞免疫疗法 | |
| JPWO2022140150A5 (https=) | ||
| US20200325241A1 (en) | Novel chimeric antigen receptors and libraries | |
| KR20250127145A (ko) | 조성물, 이를 포함하는 면역세포 및 상기 면역세포의 용도 | |
| KR20250024533A (ko) | Ras 신생 항원에 특이적인 결합 단백질 및 이의 용도 | |
| WO2021198163A1 (en) | Cd3-fusion protein and uses thereof |